Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL
NCT05392946Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide in multiple myeloma (MM), sponsored by Mayo Clinic. Started Aug 2022; status: active, not recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05392946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392946.